 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Cell Therapeutics, Inc.
 |
Cell Therapeutics, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Cell Therapeutics second quarter net loss widens Jul 26 2001 05:07 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Cell Therapeutics is a toxic avenger. The company researches small-molecule drugs to create more effective and less toxic treatments for various forms of cancer. Trisenox, its lead product (developed with the National Cancer Institute), won FDA approval to combat certain types of leukemia. The drug is still being tested on lymphomas, solid tumors, and other cancers. Cell Therapeutics is also developing Apra, a treatment for cancers that resist chemotherapy, and an agent based on Taxol, the successful cancer fighter from Bristol-Myers Squibb. The company's PanGenex subsidiary aims to sift through the human genome data in hopes of identifying possible drug applications.
COMPETITION |
 |
American Home Products Corporation (AHP)
Celltech Group plc (CLL)
Maxim Pharmaceuticals, Inc. (MAXM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.50
1-Yr. Sales Growth: 400.0%
Employees: 147
Revenue per employee: $3,401.36
KEY PEOPLE |
 |
James A. Bianco
CEO
Louis A. Bianco
CFO
CONTACT INFO |
 |
201 Elliott Ave. West, Ste. 400
Seattle, WA 98119
US
Phone: 206-282-7100
Fax: 206-284-6206
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |